logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Bausch + Lomb Completes Acquisition Of Xiidra®

Sep 29, 2023•about 2 years ago

Acquiring Company

Bausch + Lomb Corporation

Acquired Company

XIIDRA

Health CareManufacturingMedical DeviceBiotechnology

Description

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets.

Company Information

Company

Bausch + Lomb Corporation

About

Bausch + Lomb Corporation is a leading global eye health company committed to improving people’s vision. The company focuses on developing innovative products for vision correction, surgical procedures, and consumer eye care. It operates with a long-standing dedication to enhancing the visual health of patients worldwide. Bausch + Lomb is recognized for its advanced technology and quality in eye care solutions.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed